8-K: Spyre Therapeutics Updates Share Count Following Preferred Stock Conversion

Spyre Therapeutics reports an increase in outstanding common stock shares following the conversion of Series A and B preferred stock.

Summary

• Spyre Therapeutics has filed an update regarding its outstanding shares of common stock.
• This update follows the conversion of Series B Non-Voting Convertible Preferred Stock.
• As of May 29, 2024, the company had 50,782,384 shares of common stock issued and outstanding.
• On a pro forma basis, giving effect to the full conversion of Series A and B preferred stock, there are approximately 65.3 million shares of common stock issued and outstanding.

Sentiment

Score: 7

Explanation: The document is a routine update on share count following a previously announced conversion, which is neutral to slightly positive as it provides clarity to investors.

Management Comments

• Cameron Turtle, Chief Executive Officer, signed the report on behalf of the company.

Industry Context

This type of filing is standard for companies that have undergone a conversion of preferred stock to common stock, ensuring transparency with investors about the company's capital structure.

Comparison to Industry Standards

• Many biotech companies use convertible preferred stock as a means of raising capital, and subsequent conversions to common stock are a common occurrence.
• The pro forma share count is a standard metric used to understand the fully diluted ownership structure of the company.
• Comparable companies would also report similar changes in share count following such conversions.

Stakeholder Impact

• Shareholders will be interested in the updated share count as it affects their ownership percentage.
• The information provides transparency regarding the company's capital structure.

Key Dates

Keywords

common stock, preferred stock, share count, stock conversion, equity